Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rhabdoid Tumor | 12 | 2023 | 210 | 2.970 |
Why?
|
Brain Neoplasms | 38 | 2024 | 9026 | 1.680 |
Why?
|
Central Nervous System Neoplasms | 13 | 2023 | 915 | 1.480 |
Why?
|
Medulloblastoma | 8 | 2023 | 677 | 1.470 |
Why?
|
Glioma | 23 | 2024 | 3452 | 1.290 |
Why?
|
Cerebellar Neoplasms | 6 | 2023 | 586 | 1.270 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 7 | 2022 | 491 | 1.190 |
Why?
|
Neuroectodermal Tumors, Primitive | 3 | 2022 | 136 | 1.150 |
Why?
|
Teratoma | 4 | 2023 | 404 | 0.630 |
Why?
|
Brain Stem Neoplasms | 6 | 2020 | 189 | 0.630 |
Why?
|
Germinoma | 4 | 2022 | 132 | 0.610 |
Why?
|
Ependymoma | 6 | 2021 | 320 | 0.610 |
Why?
|
Chromosomal Proteins, Non-Histone | 4 | 2022 | 725 | 0.540 |
Why?
|
Neuroblastoma | 4 | 2017 | 1248 | 0.480 |
Why?
|
Taxoids | 1 | 2018 | 667 | 0.480 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2018 | 620 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 11735 | 0.440 |
Why?
|
Purines | 1 | 2017 | 606 | 0.440 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 9277 | 0.440 |
Why?
|
Child | 67 | 2024 | 80089 | 0.440 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 561 | 0.430 |
Why?
|
Aminopyridines | 1 | 2017 | 573 | 0.430 |
Why?
|
Child, Preschool | 43 | 2024 | 42193 | 0.410 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 655 | 0.400 |
Why?
|
Pyrimidinones | 3 | 2020 | 385 | 0.310 |
Why?
|
Medical Oncology | 3 | 2019 | 2317 | 0.280 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 40 | 0.270 |
Why?
|
Maximum Tolerated Dose | 3 | 2018 | 883 | 0.260 |
Why?
|
Pyridones | 3 | 2020 | 808 | 0.250 |
Why?
|
Adolescent | 42 | 2024 | 88247 | 0.250 |
Why?
|
Infant | 27 | 2024 | 36157 | 0.250 |
Why?
|
Neoplasms | 9 | 2024 | 22131 | 0.240 |
Why?
|
DNA-Binding Proteins | 4 | 2022 | 9586 | 0.240 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4252 | 0.230 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 296 | 0.230 |
Why?
|
Fireflies | 1 | 2023 | 2 | 0.230 |
Why?
|
Combined Modality Therapy | 9 | 2023 | 8516 | 0.230 |
Why?
|
Pineal Gland | 2 | 2019 | 158 | 0.220 |
Why?
|
Radiotherapy | 3 | 2008 | 1497 | 0.220 |
Why?
|
Transplantation, Autologous | 4 | 2022 | 2112 | 0.220 |
Why?
|
Molecular Targeted Therapy | 6 | 2024 | 2812 | 0.210 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13635 | 0.200 |
Why?
|
Choriocarcinoma | 1 | 2022 | 121 | 0.200 |
Why?
|
Autopsy | 2 | 2019 | 1008 | 0.200 |
Why?
|
Disease-Free Survival | 9 | 2017 | 6807 | 0.190 |
Why?
|
Neurology | 1 | 2009 | 784 | 0.190 |
Why?
|
Sarcoma | 2 | 2022 | 1800 | 0.180 |
Why?
|
Humans | 83 | 2024 | 760740 | 0.180 |
Why?
|
Stem Cell Transplantation | 2 | 2006 | 1600 | 0.180 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2020 | 42 | 0.180 |
Why?
|
Astrocytoma | 2 | 2017 | 774 | 0.170 |
Why?
|
Glioblastoma | 3 | 2023 | 3481 | 0.170 |
Why?
|
Neoplasm Proteins | 2 | 2020 | 3607 | 0.170 |
Why?
|
Craniopharyngioma | 2 | 2012 | 276 | 0.160 |
Why?
|
Keratoderma, Palmoplantar | 1 | 2018 | 17 | 0.160 |
Why?
|
Mutation | 10 | 2024 | 30015 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.150 |
Why?
|
Prognosis | 16 | 2022 | 29601 | 0.150 |
Why?
|
DNA Helicases | 1 | 2023 | 851 | 0.150 |
Why?
|
Osteosarcoma | 1 | 2004 | 896 | 0.150 |
Why?
|
Benzamides | 1 | 2023 | 1371 | 0.150 |
Why?
|
Metabolic Clearance Rate | 1 | 2018 | 361 | 0.150 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2024 | 3634 | 0.150 |
Why?
|
Quinazolines | 2 | 2015 | 1371 | 0.140 |
Why?
|
Etoposide | 4 | 2023 | 634 | 0.140 |
Why?
|
Antigens, Neoplasm | 2 | 2002 | 1985 | 0.140 |
Why?
|
Neurofibromatosis 1 | 2 | 2020 | 560 | 0.140 |
Why?
|
Neurocytoma | 1 | 2016 | 29 | 0.140 |
Why?
|
Information Dissemination | 1 | 2024 | 1126 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Emigrants and Immigrants | 1 | 2022 | 544 | 0.130 |
Why?
|
Young Adult | 17 | 2024 | 59191 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 4 | 2023 | 5672 | 0.120 |
Why?
|
Male | 40 | 2024 | 360402 | 0.120 |
Why?
|
Angiogenesis Inhibitors | 3 | 2013 | 2048 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1550 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2057 | 0.120 |
Why?
|
Pediatrics | 1 | 2009 | 3589 | 0.120 |
Why?
|
Hematologic Diseases | 1 | 2018 | 496 | 0.110 |
Why?
|
Survivors | 3 | 2024 | 2373 | 0.110 |
Why?
|
Female | 40 | 2024 | 392203 | 0.110 |
Why?
|
Transcription Factors | 3 | 2023 | 12116 | 0.110 |
Why?
|
Histones | 2 | 2022 | 2577 | 0.110 |
Why?
|
Salvage Therapy | 1 | 2020 | 1263 | 0.110 |
Why?
|
Child Mortality | 1 | 2015 | 199 | 0.110 |
Why?
|
Treatment Failure | 2 | 2018 | 2635 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2019 | 516 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10754 | 0.110 |
Why?
|
Cancer Vaccines | 1 | 2020 | 1037 | 0.110 |
Why?
|
Diabetes Insipidus | 1 | 2013 | 144 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1320 | 0.100 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2012 | 38 | 0.100 |
Why?
|
Pituitary Diseases | 1 | 2013 | 135 | 0.100 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39062 | 0.100 |
Why?
|
Retrospective Studies | 19 | 2024 | 80583 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 6473 | 0.100 |
Why?
|
Repressor Proteins | 1 | 2002 | 2985 | 0.100 |
Why?
|
Bone Neoplasms | 1 | 2004 | 2527 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2570 | 0.090 |
Why?
|
Genes, cdc | 1 | 2011 | 114 | 0.090 |
Why?
|
Infant Mortality | 1 | 2015 | 751 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2016 | 5671 | 0.090 |
Why?
|
Pituitary Gland | 1 | 2013 | 635 | 0.090 |
Why?
|
Skin Diseases | 1 | 2019 | 1094 | 0.090 |
Why?
|
Flow Cytometry | 1 | 2020 | 5863 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 11 | 0.090 |
Why?
|
Neovascularization, Pathologic | 2 | 2013 | 2644 | 0.080 |
Why?
|
Intracranial Hypertension | 1 | 2012 | 193 | 0.080 |
Why?
|
Survival Rate | 8 | 2017 | 12719 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1202 | 0.080 |
Why?
|
Pons | 1 | 2010 | 240 | 0.080 |
Why?
|
Drug Hypersensitivity | 1 | 2018 | 917 | 0.080 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5789 | 0.080 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2008 | 60 | 0.080 |
Why?
|
Genomics | 3 | 2024 | 5822 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 2020 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2015 | 1528 | 0.080 |
Why?
|
Treatment Outcome | 11 | 2020 | 64572 | 0.080 |
Why?
|
Pinealoma | 1 | 2008 | 52 | 0.070 |
Why?
|
Infratentorial Neoplasms | 1 | 2008 | 98 | 0.070 |
Why?
|
Medical Records | 1 | 2013 | 1408 | 0.070 |
Why?
|
Supratentorial Neoplasms | 1 | 2008 | 159 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 6 | 2020 | 36401 | 0.070 |
Why?
|
Adult | 19 | 2024 | 220995 | 0.070 |
Why?
|
Cyclophosphamide | 3 | 2013 | 2218 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2012 | 1185 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4570 | 0.070 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1743 | 0.070 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1245 | 0.070 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2008 | 459 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 928 | 0.070 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3447 | 0.070 |
Why?
|
Thalidomide | 2 | 2013 | 885 | 0.070 |
Why?
|
Vincristine | 2 | 2007 | 1036 | 0.070 |
Why?
|
Mesna | 1 | 2004 | 62 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5304 | 0.060 |
Why?
|
Cerebral Arteries | 1 | 2007 | 490 | 0.060 |
Why?
|
Intelligence | 1 | 2009 | 923 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1626 | 0.060 |
Why?
|
Moyamoya Disease | 1 | 2007 | 265 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4642 | 0.050 |
Why?
|
Gene Dosage | 3 | 2017 | 1217 | 0.050 |
Why?
|
Leucovorin | 1 | 2004 | 643 | 0.050 |
Why?
|
Cisplatin | 2 | 2007 | 1650 | 0.050 |
Why?
|
United States | 3 | 2023 | 72292 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3794 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2013 | 2553 | 0.050 |
Why?
|
Off-Label Use | 1 | 2024 | 185 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2019 | 2509 | 0.050 |
Why?
|
Administration, Oral | 3 | 2018 | 4010 | 0.050 |
Why?
|
Central Nervous System | 2 | 2022 | 1333 | 0.050 |
Why?
|
Methotrexate | 2 | 2007 | 1716 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 2057 | 0.050 |
Why?
|
Bone Marrow | 2 | 2002 | 2909 | 0.050 |
Why?
|
Remission Induction | 2 | 2005 | 2391 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2515 | 0.040 |
Why?
|
Camptothecin | 2 | 2017 | 591 | 0.040 |
Why?
|
Feasibility Studies | 4 | 2018 | 5239 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 367 | 0.040 |
Why?
|
Ribonuclease III | 1 | 2022 | 279 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 638 | 0.040 |
Why?
|
Infant, Newborn | 4 | 2024 | 26183 | 0.040 |
Why?
|
Radiation Injuries | 1 | 2007 | 1189 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2017 | 11118 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2004 | 13383 | 0.040 |
Why?
|
Disease Progression | 3 | 2024 | 13495 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 384 | 0.040 |
Why?
|
Contrast Media | 1 | 2012 | 5305 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2005 | 3514 | 0.040 |
Why?
|
Thymidine Kinase | 1 | 2019 | 286 | 0.040 |
Why?
|
Basal Ganglia | 1 | 2021 | 554 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 7995 | 0.040 |
Why?
|
Japan | 1 | 2022 | 1372 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3117 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 783 | 0.040 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4739 | 0.040 |
Why?
|
Oximes | 1 | 2019 | 303 | 0.040 |
Why?
|
Prodrugs | 1 | 2019 | 261 | 0.030 |
Why?
|
DNA Mismatch Repair | 1 | 2020 | 428 | 0.030 |
Why?
|
Cognition | 2 | 2016 | 6988 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12966 | 0.030 |
Why?
|
Prospective Studies | 5 | 2018 | 54364 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 617 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 1739 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1230 | 0.030 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 473 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 2224 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2016 | 205 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4569 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2010 | 0.030 |
Why?
|
Thalamus | 1 | 2021 | 1047 | 0.030 |
Why?
|
Adenoviridae | 1 | 2019 | 1084 | 0.030 |
Why?
|
Biological Availability | 1 | 2015 | 389 | 0.030 |
Why?
|
Epigenomics | 1 | 2020 | 942 | 0.030 |
Why?
|
Animals | 6 | 2023 | 168202 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2897 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17878 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 839 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10072 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2001 | 1350 | 0.030 |
Why?
|
Sirolimus | 1 | 2020 | 1533 | 0.030 |
Why?
|
Fenofibrate | 1 | 2013 | 87 | 0.030 |
Why?
|
Incidence | 3 | 2022 | 21339 | 0.030 |
Why?
|
Biopsy | 2 | 2018 | 6763 | 0.030 |
Why?
|
Morbidity | 1 | 2018 | 1750 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3601 | 0.030 |
Why?
|
Imidazoles | 1 | 2019 | 1175 | 0.030 |
Why?
|
Signal Transduction | 2 | 2013 | 23415 | 0.030 |
Why?
|
Mice, Nude | 1 | 2019 | 3606 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2004 | 2827 | 0.030 |
Why?
|
SEER Program | 1 | 2017 | 1450 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81368 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14649 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2916 | 0.020 |
Why?
|
Hearing | 1 | 2016 | 501 | 0.020 |
Why?
|
Quality of Life | 2 | 2024 | 13359 | 0.020 |
Why?
|
Viral Proteins | 1 | 2019 | 1799 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3599 | 0.020 |
Why?
|
Alleles | 2 | 2019 | 6861 | 0.020 |
Why?
|
Kidney | 2 | 2019 | 7044 | 0.020 |
Why?
|
Recurrence | 1 | 2023 | 8426 | 0.020 |
Why?
|
Zebrafish | 1 | 2022 | 3005 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2019 | 2013 | 0.020 |
Why?
|
Time Factors | 4 | 2015 | 39908 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2017 | 7050 | 0.020 |
Why?
|
Cell Cycle | 1 | 2019 | 2929 | 0.020 |
Why?
|
RNA Interference | 1 | 2019 | 2829 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8619 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 222 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4512 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7569 | 0.020 |
Why?
|
Risk Factors | 4 | 2015 | 74128 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 16968 | 0.020 |
Why?
|
Postoperative Period | 1 | 2014 | 1812 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3392 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2358 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20556 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9417 | 0.020 |
Why?
|
Boston | 2 | 2014 | 9313 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2012 | 1056 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2252 | 0.020 |
Why?
|
Retinoblastoma Protein | 1 | 2011 | 671 | 0.020 |
Why?
|
Spinal Cord | 1 | 2016 | 1807 | 0.020 |
Why?
|
Thiotepa | 1 | 2007 | 66 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 546 | 0.020 |
Why?
|
Circle of Willis | 1 | 2007 | 78 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4421 | 0.020 |
Why?
|
Optic Chiasm | 1 | 2007 | 91 | 0.020 |
Why?
|
Gene Amplification | 1 | 2011 | 1087 | 0.020 |
Why?
|
Oncogenes | 1 | 2012 | 1220 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2019 | 3037 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8209 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9310 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5334 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 701 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1158 | 0.020 |
Why?
|
Age Factors | 2 | 2015 | 18381 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2189 | 0.020 |
Why?
|
Endostatins | 1 | 2005 | 168 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1852 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 880 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2017 | 15908 | 0.020 |
Why?
|
Cause of Death | 1 | 2015 | 3683 | 0.020 |
Why?
|
Thrombospondins | 1 | 2005 | 193 | 0.020 |
Why?
|
Drug Therapy | 1 | 2008 | 503 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2014 | 2803 | 0.010 |
Why?
|
Carboplatin | 1 | 2007 | 793 | 0.010 |
Why?
|
Biomedical Research | 1 | 2019 | 3426 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8542 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3533 | 0.010 |
Why?
|
Sulfonamides | 1 | 2013 | 1977 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2005 | 592 | 0.010 |
Why?
|
Pyrazoles | 1 | 2013 | 2008 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5780 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2008 | 1336 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16572 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6961 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1404 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2008 | 11069 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2008 | 1470 | 0.010 |
Why?
|
Ploidies | 1 | 2001 | 285 | 0.010 |
Why?
|
S100 Proteins | 1 | 2001 | 217 | 0.010 |
Why?
|
Gangliosides | 1 | 2001 | 132 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5201 | 0.010 |
Why?
|
Schwann Cells | 1 | 2001 | 196 | 0.010 |
Why?
|
Genes, myc | 1 | 2001 | 390 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2005 | 1784 | 0.010 |
Why?
|
Phosphorylation | 1 | 2010 | 8311 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6483 | 0.010 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2010 | 2789 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26065 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18937 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 2067 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15250 | 0.010 |
Why?
|
Stromal Cells | 1 | 2001 | 1329 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2000 | 1008 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3492 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23974 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9171 | 0.010 |
Why?
|
Cohort Studies | 1 | 2016 | 41464 | 0.010 |
Why?
|
Comorbidity | 1 | 2007 | 10507 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12661 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12934 | 0.010 |
Why?
|